The short version of Nicotinamide mononucleotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Generally capillaries of smaller inner diameter support use of higher field strengths, due to improved heat dissipation and smaller thermal gradients relative to larger capillaries, but with the drawbacks of lower sensitivity in absorbance detection due to shorter path length, and greater difficulty in introducing buffer and sample into the capillary (small capillaries require greater pressure and/or longer times to force fluids through the capillary). The efficiency of capillary electrophoresis separations is typically much higher than the efficiency of other separation techniques like HPLC. Unlike HPLC, in capillary electrophoresis there is no mass transfer between phases. In addition, the flow profile in EOF-driven systems is flat, rather than the rounded laminar flow profile characteristic of the pressure-driven flow in chromatography columns as shown in figure 5. As a result, EOF does not significantly contribute to band broadening as in pressure-driven chromatography. Capillary electrophoresis separations can have several hundred thousand theoretical plates.
Because of that, the same predictive effect is expected for the HLB index of sucrose ester, although this index has not be built on the basis of an experimental scale, but on the basis of a calculation. By using the same notion of HLB for different categories of surfactants, it is also expected that this tool would be predictive for comparing surfactants belonging to different families, e.g. PEO surfactants and sucrose esters emulsifiers. It is not the case as long as experiments have not brought evidence that correspondences are possible between the scales applied to different surfactants families. Otherwise, it brings confusion. Non-ionic carbohydrate surfactants have a very different chemical structure and different physicochemical properties compared to polyethylene oxide surfactants family. It is the case notably for their emulsifying properties, for their sensitivity to temperature and their interaction with water through hydrogen bonding. Hence, by using the same calculated HLB scale for sucrose fatty acid esters and for polyethylene surfactants, instead of an experimental HLB scale, it is very likely that this scale will not predict properly the properties of sucrose esters. For the same reason, comparison of sucrose esters with non-ionic carbohydrate based surfactants such as Tween series is also uncertain, because the latter are grafted with polyethylene oxide chains that make them behave as PEO surfactants rather than carbohydrate surfactants.
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
Sources: en.wikipedia.org
The monofunctional monomer, often referred to as a chain stopper, controls and limits the polymerization of bifunctional monomers because the growing polymer yields chain ends devoid of functional groups and therefore incapable of further reaction.
== Men on the Moon, space stations, space shuttles (1969–1991) == The latter period of the space race began with the United States landing the first men on the Moon, and was followed by the Soviets operating the first space stations and putting the first robotic landers on Venus and Mars, the US space shuttles marking the first significant reusable space vehicles, and a cooling down of tensions with the first docking between a Soviet and American vessel.
Pakistan drew around 6.6 million foreign tourists in 2018. Pakistan boasts attractions from mangroves in the south to Himalayan hill stations in the northeast, including ancient Buddhist ruins of Takht-i-Bahi and Taxila, the 5,000-year-old Indus Valley civilisation sites such as Mohenjo-daro and Harappa, and numerous mountain peaks over 7,000 metres (23,000 feet). The northern part of Pakistan boasts numerous old fortresses, showcasing ancient architecture. It encompasses the Hunza and Chitral valleys, where the small pre-Islamic Kalasha community resides, claiming descent from Alexander the Great. Lahore, Pakistan's cultural capital, contains lots of Mughal architecture, including the Badshahi Masjid, the Shalimar Gardens, the Tomb of Jahangir, and the Lahore Fort. Following the 2005 Kashmir earthquake, The Guardian highlighted "The top five tourist sites in Pakistan" to boost tourism, featuring destinations like Taxila, Lahore, the Karakoram Highway, Karimabad, and Lake Saiful Muluk. Festivals and government initiatives aim to promote Pakistan's cultural heritage. In 2015, the World Economic Forum ranked Pakistan 125th out of 141 countries in its Travel & Tourism Competitiveness Report.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.